These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 26207428)
21. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients. Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185 [TBL] [Abstract][Full Text] [Related]
22. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831 [TBL] [Abstract][Full Text] [Related]
24. Abiraterone-induced rhabdomyolysis: A case report. Moore DC; Moore A J Oncol Pharm Pract; 2017 Mar; 23(2):148-151. PubMed ID: 26637407 [TBL] [Abstract][Full Text] [Related]
26. Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer. Afshar M; Al-Alloosh F; Pirrie S; Rowan C; James ND; Porfiri E Anticancer Res; 2015 Feb; 35(2):1057-63. PubMed ID: 25667494 [TBL] [Abstract][Full Text] [Related]
27. [A multicentric, randomized, double-blind, placebo-controlled Phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN): AUO study AP 82/14]. Rexer H; Hammerer P Urologe A; 2016 Mar; 55(3):395-7. PubMed ID: 26820656 [No Abstract] [Full Text] [Related]
28. [Pharmacological properties of abiraterone acetate (ZYTIGA® tablet 250 mg), a new drug for the treatment of castration-resistant prostate cancer, and results of its clinical studies]. Iwata M; Tsutsumi K; Harada Y Nihon Yakurigaku Zasshi; 2015 May; 145(5):260-5. PubMed ID: 25958914 [No Abstract] [Full Text] [Related]
29. Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108. Liu M; Chen P; Li T Eur Urol; 2024 Jun; 85(6):e176-e177. PubMed ID: 38135561 [No Abstract] [Full Text] [Related]
35. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481 [TBL] [Abstract][Full Text] [Related]
36. Multidisciplinary consensus: a practical guide for the integration of abiraterone into clinical practice. Woo HH; Begbie S; Gogna K; Mainwaring PN; Murphy DG; Parnis F; Steer C; Davis ID Asia Pac J Clin Oncol; 2014 Sep; 10(3):228-36. PubMed ID: 25132163 [TBL] [Abstract][Full Text] [Related]
37. Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer. Dellis A; Papatsoris AG Expert Opin Biol Ther; 2014 Jan; 14(1):7-10. PubMed ID: 24074253 [TBL] [Abstract][Full Text] [Related]
38. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity. Schutz FA; Buzaid AC; Sartor O Crit Rev Oncol Hematol; 2014 Sep; 91(3):248-56. PubMed ID: 24613528 [TBL] [Abstract][Full Text] [Related]
39. Do All High- and Intermediate-Risk Patients With Metastatic Castration-Resistant Prostate Cancer Really Benefit From Abiraterone? Addeo A; Bahl A J Clin Oncol; 2016 Feb; 34(4):387. PubMed ID: 26598758 [No Abstract] [Full Text] [Related]
40. Making progress on progression in metastatic prostate cancer. Armstrong AJ; Halabi S J Clin Oncol; 2015 Apr; 33(12):1322-4. PubMed ID: 25667271 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]